Pharmaceutical Executive, May 1, 2009 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, May 1, 2009
Features
Bank on IT
By George Koroneos, Online Content & News Editor
Tough economic tmes call for a bold approach to evolving information technology solutions.
Ad(Ventures) in Pharmaland
By Brittany Agro
Despite the downside in ad spend, an upside remains in the digital space that's wide open for exploration.
2009 PharmExec Top 50
We leap tall buildings to bring you the definitive guide to the world's top pharmaceutical companies.
Why All the Bad Buzz?
European docs have always been down on pharma—but now the US is catching on. Perhaps pharma has oversold the "service model."
The Shakeout
By Ben Bonifant
When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game.
The Fate of Mannkind
By Cassandra Blohowiak, contributing editor
Al Mann has sunk almost $1 billion of his own money into a new insulin delivery system. Will FDA be persuaded?
Columns
Your Most Precious Asset
Eleven Ways to attract and retain top advertising talent.
Behavior and the Bottom Line
In an era of shrinking marketing budgets, increase ROI with behavioral science-based marketing.
Weathering the Storm
Marketers must stress that maintaining good health behaviors is one of the best things people can do to survive a down market.
A Day Late and a Dollar Short
Pharma marketers face a crisis in digital media. But there's a way to turn it around.
Washington Report
Compared to What?
By Jill Wechsler
Pharma fears comparative effectiveness research will focus on costs and stymie personalized medicine.
From the Editor
Another Dimension
By Patrick Clinton
Our 3-D cover jumps off the page. But the real question for us (and for you) is how do we get everything else to connect?
Column
Compensation Overkill
By Sander A. Flaum
Congress—and the public—needs to take a deep breath before making a big mistake.

ADVERTISEMENT

Click here